Novartis AG (SWX:NOVN)
121.60
+1.98 (1.66%)
At close: Mar 9, 2026
Novartis AG Revenue
In the year 2025, Novartis AG had annual revenue of $56.67B USD with 9.57% growth. Novartis AG had revenue of $13.86B in the quarter ending December 31, 2025, with 2.23% growth.
Revenue
$56.67B
Revenue Growth
+9.57%
P/S Ratio
5.23
Revenue / Employee
$752.97K
Employees
75,267
Market Cap
235.20B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 56.67B | 4.95B | 9.57% |
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.36B |
| Galderma Group AG | 4.16B |
| Lonza Group AG | 6.53B |
| Alcon | 8.25B |
| Sandoz Group AG | 8.85B |
| Straumann Holding AG | 2.61B |
| Sonova Holding AG | 3.85B |
| Galenica AG | 4.03B |
Novartis AG News
- 3 days ago - Novartis AG (NVS) Shareholder/Analyst Call Prepared Remarks Transcript - Seeking Alpha
- 3 days ago - Novartis (NVS) Shareholders Approve Key Resolutions at Annual Meeting - GuruFocus
- 3 days ago - Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting - GlobeNewsWire
- 4 days ago - Novartis AG (NVS) Shares Down 3.08% on Mar 5 - GuruFocus
- 5 days ago - Novartis And Henrietta Lacks' Family Reach A Settlement - Forbes
- 6 days ago - Novartis AG (NVS) Stock Price Down 3.43% on Mar 3 - GuruFocus
- 6 days ago - Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now - The Motley Fool
- 6 days ago - Commit fully to the role you’re in now, and your career may thank you later: Novartis CEO Vas Narasimhan - CNBC